Publication date: Jul 08, 2025
Parkinson’s disease is the second most common neurodegenerative disorder. In advanced Parkinson’s disease, subcutaneous (SC) infusion therapies represent minimally invasive and reversible treatment options. In the United Kingdom (UK), licensed SC infusion therapies include apomorphine and foslevodopa-foscarbidopa; both represent effective and generally well-tolerated therapies, although uncertainties regarding their relative efficacy, safety and costs remain. The relative efficacy and safety of apomorphine and foslevodopa-foscarbidopa was assessed via Bucher indirect treatment comparison (ITC) of TOLEDO (NCT02006121) and M15-736 (NCT04380142) data, with findings used to support a cost-minimisation analysis (CMM). Thirteen outcomes were evaluated. Efficacy and safety outcomes were measured as mean differences and risk differences, respectively. The CMM, conducted from a UK healthcare payer perspective, considered treatment acquisition and concomitant therapy costs over a 6. 34-year horizon (obtained from a published observational study). Bucher ITC results provided evidence for a comparable efficacy for apomorphine and foslevodopa-foscarbidopa in advanced Parkinson’s disease. ITCs also indicated comparable safety, although a trend in favour of apomorphine was identified for hallucinations and most infusion site reactions assessed. The CMM demonstrated a clear per-patient cost benefit for apomorphine versus foslevodopa-foscarbidopa (lb120,173. 70), primarily driven by lower drug acquisition costs. The main difference between UK licensed SC infusion therapies for advanced Parkinson’s disease relates to cost as opposed to clinical outcome, with some evidence for improved tolerability of apomorphine. This supports the continued use of apomorphine as first-line SC infusion treatment for advanced Parkinson’s disease in UK clinical practice.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s Disease |
| disease | MESH | neurodegenerative disorder |
| drug | DRUGBANK | Apomorphine |
| disease | MESH | hallucinations |
| drug | DRUGBANK | Trihexyphenidyl |
| drug | DRUGBANK | Profenamine |
| drug | DRUGBANK | Trestolone |
| drug | DRUGBANK | Levodopa |
| disease | MESH | dyskinesias |
| disease | MESH | syndrome |
| drug | DRUGBANK | Hexocyclium |
| drug | DRUGBANK | S-Arsonocysteine |
| disease | MESH | cellulitis |
| disease | MESH | erythema |
| drug | DRUGBANK | Morphine |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Aspartame |
| disease | MESH | uncertainty |
| disease | MESH | insomnia |
| drug | DRUGBANK | Ranitidine |
| pathway | REACTOME | Release |
| disease | MESH | Movement Disorder |